Previous 10 | Next 10 |
A once high-flying drug might be poised to take to the skies again. Amarin (NASDAQ: AMRN) released clinical trial results Monday that showed its Vascepa heart medicine effectively reduced cardiovascular events in patients with decreased kidney function. The late-stage trial is a...
A post hoc subgroup analysis from the large-scale REDUCE-IT trial showed showed reduced cardiovascular ((CV)) events in patients with compromised renal function who received Amarin's (AMRN) Vascepa (icosapent ethyl). The results were presented at American Society of Nephrology Kidney Week.Adv...
Patients with decreased renal function prior to treatment with VASCEPA or placebo had higher rates of cardiovascular events than the overall population studied in REDUCE-IT REDUCE-IT patients with decreased renal function prior to treatment showed similarly favorable relative ri...
ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The Strategy performed well in the third quarter in an en...
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 23, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the presentation of real-world evidence data at American Society of Nephrology (ASN) Kidney Week 2020, held virtually from October 22 – October 25, 2020, addi...
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin senior management to discuss the company's third quarter 2020 financial results and provide an operational...
Gainers: [[FSI]] +24.2%. [[AMRN]] +3.8%. [[CHWY]] +3.8%. [[EIGR]] +3.7%. [[AFI]] +3.6%.Losers: [[KC]] -8.9%. [[MRTN]] -7.9%. [[NTN]] -6.6%. [[SOS]] -5.5%. [[RLGY]] -4%. For further details see: AMRN, CHWY, RLGY and KC among after-hours movers
Amarin (AMRN) announces that Vascepa was found to significantly reduce ischemic events in patients with prior percutaneous coronary intervention or PCI, citing a post hoc subgroup analyses of the REDUCE-IT studyVascepa, compared with placebo, significantly reduced primary composite first and ...
VASCEPA ® , c ompared with placebo, significantly reduced primary composite first and total MACE (m ajor a dverse c ardiovascular e vents ) in post hoc exploratory analyses of patients with a history of PCI by 34...
Back in 1993, when drugmaker Amarin 's (NASDAQ: AMRN) shares first hit the market, it might have cost you $1,425 to buy one share (adjusted for splits). Go forward a few decades, and that one share now costs a little over $5. Clean Energy Fuels (NASDAQ: CLNE) , meanwhile, hi...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...